



April 7-8
2022
Congress Center
Basel | Switzerland

6th AMR Conference

Novel Antimicrobials & AMR Diagnostics

amr-conference.com
#AMRconference

Organisation: BIOCOM AG | Jacobsenweg 61 | 13509 Berlin
Christin Hohmann | amr@biocom.de | Tel. +49 (0)30 264921-55

BIOCOM®

At a glance

Conference Day 1

09:00–11:00	Pre-conference Meeting General assembly BEAM Alliance	Room Rio page 5
11:00–11:30	Networking Break	
11:30–13:00	Pre-conference workshop Workshop with a Focus on drug development	Room Osaka page 5
11:30–13:00	Pre-conference workshop NCCR Antiresist Networking event (invitation only)	Room Rio page 5
13:00–21:30	Registration, poster presentations and exhibition open	
	Opening Keynote Plenary talk	
14:00–15:30	AMR innovation: Finally on track to market & patients?	Room Sydney page 6
15:30–16:00	Coffee Break with poster session & exhibition	
15:30–20:30	1-to-1 Partnering Meetings	Room Singapore
16:00–17:30	Parallel Tracks	
	<div> A new era for TB drug development: From innovation trial design to efficient drug regiments Room Osaka page 7 </div> <div> Diagnostics in AMR: Focus on market needs & learnings from COVID-19 innovations Room Rio page 6 </div> <div> Impact of pull incentives on the R&D portfolio: Current status & perspectives Room Sydney page 6 </div>	
17:30–18:00	Coffee Break with poster session & exhibition	
18:00–19:30	Start-up pitching session	Room Sydney page 7
19:30–21:30	Joint reception & Dinner in the exhibition hall	

Day 1
7 April

2



SSID: Free-Messe-Basel

Free SMS Login (one login for each device)

Conference Day 2

08:00–18:30	Registration, poster presentations and exhibition open		
08:30–10:00	Parallel Tracks		
	Focus on One Health	Novel Technologies to combat AMR (CRISPR, AI, phages, mRNA)	Animal infection models & other tools for preclinical efficacy
	Room Sydney page 8	Room Osaka page 8	Room Rio page 8
10:00–10:45	Coffee break with poster session & exhibition		
10:00–16:30	1-to-1 Partnering Meetings		Room Singapore
	Plenary Session		
10:45–12:00	From One Health to SDG: Why there is no option than to fight AMR on a global scale		Room Sydney page 9
12:00–13:30	Lunch Break with poster session & exhibition		
12:00–13:30	UK Government hosted lunch reception with Dame Sally Davies, UK Special Envoy on AMR (prior registration required)		Room San Francisco page 9
13:30–14:30	Parallel Tracks		
	Focus on clinical development/trials & regulatory perspectives	Vaccines back on track to combat AMR: New approaches & challenges	Diagnostic programmes
	Room Sydney page 9	Room Osaka page 10	Room Rio page 10
14:30–15:00	Networking Break		
15:00–16:00	Parallel Tracks		
	Focus on fungal infections: Current trends & developments – (shared lessons learned for AMR?)	Focus on clinical needs: Which innovation in AMR is in demand?	Therapeutic programmes
	Room Sydney page 10	Room Osaka page 11	Room Rio page 11
16:00–16:30	Coffee break with poster session & exhibition		
	Plenary Session		
16:30–17:30	Cooperation as new normal? New cooperation models (PPPs, investors, Pharma/SMEs, public entities) – from early stage to clinical development		Room Sydney page 11
17:30–18:30	Closing reception in the exhibition hall		

Day 2
8 April

Partnering

Meet the right people and take your business/collaboration idea, technology or R&D project to the next level.

The #AMRconference is the perfect place to meet with existing and new potential partners and investors from the AMR community in 1:1 partnering meetings.

Our online partnering tool allows you to identify potential partners and manage all your meeting requests face-to-face and virtually.

During the AMR Conference 2022, 7 – 8 April 2022, all partnering meetings will take place on-site. Therefore, we will have a designated partnering area as well as the opportunity to meet exhibitors directly at their booth.

The pre-scheduled one-to-one meetings take place as follows:

Day 1
7 April

Day 1, 7 April: 15:30–23:00
Day 2, 8 April: 10:00–16:30

The length of each meeting slot is 25 minutes.

Please check your individual meeting schedule for times and locations of your confirmed meetings.

Meeting locations:

Room Singapore

Need help? Please see the Partnering Help Desk in front of Room Singapore.

The partnering stays open even after the AMR Conference 2022. Between 9 and 14 April, we will activate the video-chat function, so that you can continue to meet and thus make the most out of your participation.

Pre-conference

Room Rio

09:00–11:00 **BEAM Alliance General Assembly**
for BEAM members only



Pre-conference

Room Osaka

11:30–13:00 Pre-conference workshop (registration required)
Workshop with a Focus on drug development
organized by Novo Repair Impact Fund



Introduction

Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria

Putting the puzzle pieces together

*Enza Di Modugno, Global Head Infectious Disease and Immunology,
Pharma Partnering, F. Hoffmann-La-Roche Ltd, Basel, Switzerland*

Chemistry, production, stability

*Aleksandar Danilovsky, Chief Scientific Officer (CSO),
Xellia Pharmaceuticals, Copenhagen, Denmark*

Discussion

Day 1
7 April

Pre-conference

Room Rio

11:30–13:00 Pre-conference workshop (on invitation only)
Networking event by AntiResist
organized by NCCR AntiResist



Plenary Session

Room Sydney

14:00–15:30 AMR innovation: Finally on track to market & patients?

Intro talks by:

Marc Gitzinger, BioVersys AG & BEAM Alliance

Martin Heidecker, AMR Action Fund

Aleksandra Opalska, European Commission

Marc Gitzinger, BioVersys AG & BEAM Alliance

Panel Debate with all speakers:

Erin Duffy, CARB-X

William Stubbings, Roche

Valeria Gigante, WHO

Bruce Altevogt, EFPIA

Parallel Track

Room Sydney

16:00–17:30 Impact of pull incentives on the R&D portfolio: Current status & perspectives

Kevin Outterson, Boston University & CARB-X

Lesley Ogilvie, Global AMR R&D Hub

Peter Beyer, WHO - SECURE Initiative

Colm Leonhard, NICE

Jean-Baptiste Perrin, European Commission

David Ridley, Duke Margolis

Day 1
7 April

Parallel Track

Room Osaka

16:00–17:30 A new era for TB drug development: From innovation trial design to efficient drug regimens

hosted by the IMI AMR Accelerator & in cooperation
with the Unite4TB/Era4TB consortia



Michel Pieren, BioVersys

Andreas Diacon, TASK

Michael Hoelscher, University of Munich

Michel Pieren, BioVersys

David Barros-Aguirre, GSK

Parallel Track

Room Rio

16:00–17:30 **Diagnostics in AMR: Focus on market needs & learnings from COVID-19 innovations**

Till Bachmann, University of Edinburgh

Stefanie Deinhard-Emmer, University Clinic of Jena

Jessica Caffrey, QuantumDx

Cecilia Ferreyra, FIND, the global alliance for diagnostics

Plenary Session

Room Sydney

18:00–19:30 **Start-up pitching session**

hosted by  Prize Sponsor  VOSSIUS

Start-ups in running order: Invitris, Amprologix, Selmod GmbH/LLC, AdjuTec Pharma, Myxobiotics, smartbax - antibiotics of a new generation!, Sefunda AG, PreOccu, HHV Biotech, Arivin therapeutics, LimmaTech Biologics

Day 1
7 April

Parallel Track

Room Sydney

08:30–10:00 Focus on One Health

hosted by the Global AMR Hub



Lesley Ogilvie, Global AMR R&D Hub

Amit Khurana, Centre for Science and Environment (CSE)

Jomana Musmar, OIDP/PACCARB

Tine Rikke Jorgensen, World Health Organization (WHO)

Ghada Zoubiane, The International Centre for Antimicrobial Resistance Solutions (ICARS)

Parallel Track

Room Osaka

08:30–10:00 Novel Technologies to combat AMR (CRISPR, AI, phages, mRNA)

in cooperation with the NCCR AntiResist network



Christoph Dehio, NCCR AntiResist,

Jon Stokes, Phare Bio

Martin Loessner, ETH Zurich

Knut Drescher, University of Basel, Biozentrum

Mattia Zampieri, ETH Zurich

Sundar Hengoju, Leibniz/Hans Knöll Institute

Day 2
8 April

Parallel Track

Room Rio

08:30–10:00 Animal infection models & other tools for preclinical efficacy

in cooperation with IMI AMR Accelerator & further partners



Peter Jackson, INFEX Therapeutics Ltd

Jennifer Hoover, Infectious Diseases Research Unit, GSK

Glenn Dale, BioVersys

Erin Duffy, CARB-X

Robin Dumas, Vibioshen

Plenary Session

Room Sydney

10:45–12:00 **From One Health to SDG:
Why there is no option than to fight AMR on a global scale**

Peter Beyer, AMR Division, World Health Organization (WHO)

Panel Debate with all speakers:

Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance

*Jomana Musmar, The Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria (PACCARB)*

Jean-Pierre Paccaud, GARDP

Emma Hannay, FIND, the global alliance for diagnostics

UK Lunch Reception

Room San Francisco

12:00–13:30 **Lunch reception with Dame Sally Davies,
UK Special Envoy on AMR**

hosted by Her Majesty's Ambassador to Switzerland Jane Owen
Participation by invitation only

Day 2
8 April

Parallel Track

Room Sydney

13:30–14:30 **Focus on clinical development/trials & regulatory
perspectives**

Florence Séjourné, Da Volterra & BEAM Alliance

Marc Bonten, Utrecht University/ECRAID

Najy Alsayed, Menarini

Radu Botgros, European Medicines Agency (EMA)

William Stubbings, Roche

Parallel Track

Room Osaka

13:30–14:30 Vaccines back on track to combat AMR: New approaches & challenges

Bernhard Kerscher, Paul-Ehrlich-Institut

Cristina Alaimo, LimmaTech Biologics AG

Isabel Frost, World Health Organization (WHO)

Juanjo Infante, VAXDYN

Parallel Track

Room Rio

13:30–14:30 Diagnostic programmes

in cooperation with

Till Bachmann, University of Edinburgh

Anita Suresh, FIND, the global alliance for diagnostics

Christian Brandt, Nanozoo GmbH

Belinda Ngongo, Illumina



Day 2
8 April

Parallel Track

Room Sydney

15:00–16:00 Focus on fungal infections: Current trends & developments – (shared lessons learned for AMR?)

Mark Jones, Basilea Pharmaceutica International Ltd.

Maja Weisser, University of Basel

Rienk Pypstra, Pfizer

Hatim Sati, World Health Organization (WHO)

Parallel Track

Room Osaka

15:00–16:00 **Focus on clinical needs: Which innovation in AMR is in demand?**

Valeria Gigante, World Health Organization (WHO)

Apostolos Armaganidis, ATTIKON University Hospital

Andreas Wimmer, University Hospital Basel

Cecilia Ferreyra, FIND, the global alliance for diagnostics

Parallel Track

Room Rio

15:00–16:00 **Therapeutic programmes**

Frédéric Peyrane, BEAM Alliance

Company presentations by:

Glenn Dale, BioVersys

Peter Jackson, INFEX Therapeutics Ltd

Florence Séjourné, Volterra

Georges Gaudriault, Deinove

Cindy Fevre, Pherecydes

Day 2
8 April

Plenary Session

Room Sydney

16:30–17:30 **Cooperation as new normal? New cooperation models (PPPs, investors, Pharma/SMEs, public entities) – from early stage to clinical development**

Marc Lemonnier, BEAM Alliance & ARPEGE, Antabio

Panel Debate with all speakers:

Erin Duffy, CARB-X

Sebastian Kreuz, Boehringer Ingelheim

Jürgen Popp, Leibniz Institute of Photonic Technology


Holger Zimmermann, AiCuris

Floor Map

2nd floor



3rd floor



- Exhibitor Booths
- Partnering Area
- Catering

Poster Exhibition

No.	Title	Corresponding Author
Therapeutics		
1	Development of antibacterial compounds targeting <i>Chlamydia trachomatis</i>	Katarina Vielfort , Department of Molecular Biology Umeå University
2	TRANSLOCATION-transfer (TT)	Mathias Winterhalter , Jacobs University
3	Gram-negative bacteria contain a conserved antibiotic target site accessible from outside	Seyed Majed Modaresi , Structural Biology and Biophysics Department, Biozentrum, University of Basel
4	In vivo efficacy of BV100 in mouse models of <i>Acinetobacter baumannii</i> infections	Glenn Dale , BioVersys
5	Recurring Issues in the Development of Vaccines against AMR Infections: Results from the COMBINE Vaccine Expert Workshop	Linda Marchioro , Paul-Ehrlich-Institut, Division of Microbiology
6	Structure optimization of Albicidin, a new antibacterial lead structure	Marcel Kulike , Technische Universität Berlin
7	Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors	Alistair Farley , Department of Chemistry INEOS Oxford Institute, University of Oxford
Diagnostics		
8	A new pre-amplification method to detect very low DNA copy numbers of (multi-) resistant pathogens in complex samples	Martin Reinicke , InfectoGnostics Research Campus Jena
9	Antimicrobial Resistance Gene Distribution in ESBL-Producing <i>Escherichia coli</i> Isolates from Animals in Greece	Sascha Braun , InfectoGnostics Research Campus Jena
10	Automated antimicrobial susceptibility predictions and genotypes among Enterobacteriaceae using Illumina and ONT sequencing data	Stephan Beisen , Ares Genetics
12	Miniaturised agar plates: microfluidic tools to determine and study antibiotic resistance in bacteria	Petra Jusková , Department of Biosystems Science and Engineering, ETH Zurich

No.	Title	Corresponding Author
Enabling Technology		
13	Microfluidic platform for continuous perfusion of transwell-based barrier models	Amanzhol Kurmashev , Department of Biosystems Science and Engineering, ETH Zurich
14	reComBat: Batch effect removal in large-scale multi-source gene-expression data integration	Sarah Brüningk/Michael Adamer , Department of Biosystems Science and Engineering, ETH Zurich
15	Rapid detection of Antimicrobial resistance by Immuno-magnetic separation.	Roger Marginet i Assens , NG Biotech
16	Highly Efficient Immobilization of Bacteriophages on Magnetic Particles for the Capture, Separation, and Detection of Bacteria	Caitlin Carmody , Cornell University Food Science Department
17	Fragment based design of mycobacterial thioredoxin reductase inhibitors: from a fragment screening to novel inhibitors	Friederike Füsser , Westfälische Wilhelms-Universität
18	The MilliDrop Analyzer : an enabling technology for antimicrobial drugs development	Laurent Boitard , MilliDrop
19	Fragment class with carbapenemase inhibition and antibacterial activity	Daniel Norman , Technische Universität München
20	A cloud-based analytics platform for antimicrobial susceptibility testing of Mycobacterium tuberculosis from WGS data	Chloé Loiseau , enGene Statistics GmbH
Others		
21	Appreciative Inquiry, Sequential Transformative Mixed method, Knowledge and Attitude of antimicrobial Resistance amongst Community Pharmacists in Thailand	Rojjares Netthong , School of Pharmacy The University of Lincoln, Joseph Banks Laboratories
22	National Center of Competence in Research AntiResist: New approaches to combat antibiotic-resistant bacteria	Anne-Cécile Hiebel , Biozentrum, University of Basel

A big thank you to our sponsors!

Sponsors:



Supporting Partners:



Media Partners:

